Expression of Concern
This article is currently under investigation. We strongly recommend that this article is not cited until the investigation is completed.
This article is currently under investigation. We strongly recommend that this article is not cited until the investigation is completed.
Research Paper Volume 12, Issue 11 pp 11025—11041
LncRNA ADAMTS9-AS2 inhibits gastric cancer (GC) development and sensitizes chemoresistant GC cells to cisplatin by regulating miR-223-3p/NLRP3 axis
Figure 3. LncRNA ADAMTS9-AS2 regulated GC cell proliferation, viability, mobility and EMT by targeting miR-223-3p. CCK-8 assay was used to measure cell proliferation in (A) SGC7901 cells and (C) BGC-823 cells. Cell counting assay by trypan blue staining method was performed to determine cell viability in (B) SGC7901 cells and (D) BGC-823 cells. (E, F) Transwell assay was conducted to measure cell migration in GC cells. Western Blot was employed to examine the expressions of EMT associated proteins (N-cadherin, E-cadherin and Vimentin) in (G, H) SGC7901 cells and (I, J) BGC-823 cells. Each experiment repeated at least 3 times. “NS” represented “no statistical significance”, *P < 0.05, **P < 0.01.